Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy

Overview of attention for article published in Immunobiology, May 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#20 of 1,454)
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

blogs: 1 blog
twitter: 4 X users

patent: 4 patents
facebook: 1 Facebook page

Readers on

mendeley: 50 Mendeley

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 2,250 followers.

RT @LambrisJD: Back in 2016 we first posited that C3 inhibition would afford therapeutic benefit in C3G https://t.co/WPyb8uDgxT Compstati…

Back in 2016 we first posited that C3 inhibition would afford therapeutic benefit in C3G https://t.co/WPyb8uDgxT Compstatin Cp40/AMY-101 could restore complement regulation in C3G models. Happy to see that pegcetacoplan now shows efficacy in Phase II:…

Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. https://t.co/OJuHJMjan8

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.